Several Hsp90 inhibitors have been shown to inhibit and degrade BCR-ABL. In vitro studies unveiled that Hsp90 inhibitors alone or in combination with other inhibitors downregulate BCR-ABL levels in wild-type and TKI-resistant CML cells. Here, HSP90AA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.